Mildronate, an inhibitor of carnitine biosynthesis, induces an increase in gamma-butyrobetaine contents and cardioprotection in isolated rat heart infarction [PDF]
, 2006 The inhibition of gamma-butyrobetaine (GBB) hydroxylase, a key enzyme in the biosynthesis of carnitine, contributes to lay ground for the cardioprotective mechanism of action of mildronate.
Loca, Dagnija +6 more
core +1 more source
Mildronate treatment alters γ-butyrobetaine and
, 2011 Objectives In this study, we aimed to investigate the effects of long-term administration of the cardioprotective drug mildronate on the concentrations of l-carnitine and γ-butyrobetaine in healthy volunteers.
Ilze Konrade +15 more
core +1 more source
Study of the cardioprotective metabolic effects of mildronate [PDF]
, 2020 Universitatea de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, Disciplina de medicină internă-semiologie, Chișinău, Republica Moldova, Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină și Farmacie „Nicolae ...
Chetruș, Olga
core +1 more source
Кардиоваскулярная терапия и профилактика, 2012 Aim. To compare the effects of Mildronate and hormone replacement therapy (HRT) with estradiol (1 mg) and drospirenone, DSPR (2 mg) on circadian blood pressure (BP) profile, arterial structure and function, and vascular stiffness parameters in women with
S. N. Tolstov +4 more
doaj +1 more source
The synthesis of N-(4-aryl-thiazol-2-yl)-N1-(4,5,6,7-tetrahydro-3H-azepin-2-yl)-hydrazine hydrobromides and the cardioprotective activity of (41-methoxyphenyl-thiazol-2-yl) derivative [PDF]
Pharmacia, 2021 A novel series of N-(4-aryl-thiazol-2-yl)-N1-(4,5,6,7-tetrahydro-3Н-azepin-2-yl)-hydrazine derivatives were synthesized by interaction of equimolar quantities of substituted α-bromacetophenones with thiosemicarbazide and characterized on the basis of ...
Sergii А. Demchenko +5 more
doaj +3 more sources
MELDONIUM: EFFECTIVE ACTION POINTS
Кардиоваскулярная терапия и профилактика, 2013 The paper is focused on hypoxia and cell ischemia as universal pathogenetic mechanisms of disease development, which can be addressed by both etiotropic and pathogenetic therapy. The latter is represented by the so-called metabolic correctors. At present,
A. L. Vertkin +4 more
doaj +1 more source
NEW PATHOGENETIC FACTORS OF ATHEROSCLEROSIS DEVELOPMENT AND POTENTIAL THERAPEUTIC APPROACHES
Кардиоваскулярная терапия и профилактика, 2013 It has been demonstrated that one of the factors in the pathogenesis of atherosclerosis, with the subsequent development of myocardial infarction (MI), stroke (S), or sudden death (SD), is trimethylaminoxide (TMAO), the end-product of dietary choline ...
I. Ya. Kalvinsh
doaj +1 more source
Carnitine congener mildronate protects against stress- and haloperidol-induced impairment in memory and brain protein expression in rats [PDF]
, 2014 The present study investigates the efficacy of mildronate, a carnitine congener, to protect stress and haloperidol-induced impairment of memory in rats and the expression of brain protein biomarkers involved in synaptic plasticity, such as brain-derived ...
Beitnere, Ulrika +5 more
core +1 more source
Meldonium (Mildronate): Primum nоn nocere
Pharmacological Research, 2016 [No abstract available]
openaire +4 more sources
Rat spinal ganglia in assessment of protective action of antioxidants: A morphological study
Medicina, 2017 Background and objective: Mercury pollution is one of the most pressing environmental problems. Therefore, the impact of mercury on human body, the nervous system in particular, remains topical.
Liudmyla M. Sokurenko +4 more
doaj +1 more source